Earnings Call Transcript January 30, 2025 Sanofi misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were ...

Sanofi SA (SNY) reports robust sales growth driven by Dupixent and vaccines, while planning a significant share buyback to ...

Deutsche Bank (ETR:DBKGn) analyst Emmanuel Papadakis upgraded Sanofi (NASDAQ:SNY) stock from Sell to Hold and increased the ...

Deutsche Bank has upgraded Sanofi (NASDAQ:SNY) to hold from sell, citing the company's Q4 earnings report. The investment ...

Sanofi (SAN:FP) (NASDAQ: NASDAQ:SNY) saw its price target increased by Leerink Partners from €113.00 to €120.00, while the firm maintained an Outperform rating on the company's shares. Currently ...

Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant Approval based on positive results from the IMROZ phase 3 study ...

Bernstein SocGen Group revised its price target for Regeneron (NASDAQ:REGN) Pharmaceuticals (NASDAQ: REGN) to $1,000 from the previous $1,070, while retaining an Outperform rating on the stock.

The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

The global vaccines market is projected to grow by $194 billion from 2025 to 2029, with an annual growth rate of nearly 23%, according to a report by Technavio. The expansion is fueled by increased ...

Oppenheimer launched its coverage of Alumis (NASDAQ:ALMS) with an Outperform recommendation and a 12–18-month price target of ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...